Company Logo

23.09 USD

-0.02 (-0.07%)

Last updated Nov 8, 2:30 PM

Yesterday High

$23.19

Yesterday Low

$22.70

52w High

$32.80

52w Low

$22.33

Market Cap.

$1.5B

52w Change

-28.19%

This is a preview of the full version of Prosperse

Trending News

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical Trial
Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endo...

Rinatabart sesutecan (Rina-S), an investigational folate receptor-alpha (FRα)-targeted, Topo1 antibody-drug conjugate, demonstrated promising anti-tumor activity in a Phase 1/2 clinical trial for heavily pretreated patients with ovarian and endometrial cancers.

Genmab A/S

Sep 15, 2024

Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference
Genmab to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Genmab A/S, a biotechnology company, announced that its CEO and CFO will participate in a fireside chat at the Morgan Stanley Global Healthcare Conference on September 4, 2024.

N/A

Aug 26, 2024

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Genmab A/S, a biotechnology company, disclosed transactions in its shares made by its managerial employees and their closely associated persons.

Genmab A/S

Aug 13, 2024

Capital Increase in Genmab as a Result of Employee Warrant Exercise
Capital Increase in Genmab as a Result of Employee Warrant Exercise

Genmab A/S, a biotechnology company, announced an increase in its share capital by 28,193 shares due to the exercise of employee warrants. The increase corresponds to approximately 0.04% of the company's share capital, and the proceeds to the company are approximately DKK 29.3 million.

N/A

Aug 13, 2024

Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?
Should You Buy AbbVie (ABBV) After Q2 Beat, Guidance Raise?

AbbVie reported strong Q2 results, beating estimates for earnings and sales. The company's ex-Humira drugs, such as Rinvoq and Skyrizi, performed well, offsetting the decline in Humira sales. AbbVie raised its 2024 guidance for earnings and sales, driven by the strong performance of its newer drugs.

Zacks Equity Research

Aug 1, 2024

Login to view more news

Dive into the world of investing with Prosperse

Explore our recent articles to learn more about how Prosperse can help you achieve your financial goals.

Read more news from Prosperse